ADVERUM BIOTECHNOLOGIES INC (ADVM)

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of...

Which stocks are moving after the closing bell on Tuesday?

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023

ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the fourth quarter of 2023.

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adverum Biotechnologies (NASDAQ:ADVM) just reported results for the fourth quar...

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety...

Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop

There are plenty of penny stocks ready to pop but we have to remember that penny stocks are extremely risky, too.

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene...

Stocks on the Launchpad: The Next 3 Market Sensations

Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments

Unleash Massive Returns With These 3 Top Penny Stocks

Our economy is doing well, and these top penny stocks are in position to benefit from this. Invest now and see strong returns.

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction...

Monday Sector Leaders: Biotechnology, Semiconductors

Adverum Biotechnologies announces $127.5M private placement financing (NASDAQ:ADVM)

Adverum Biotechnologies plans to raise $127.5 million by selling approximately 106.25 million shares of its common stock in a private placement.

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital,...

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting...

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial -

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of...

Monday Sector Laggards: Biotechnology, Drugs

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

- Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically...

Adverum Biotechnologies to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

Adverum Biotechnologies appoints Andrew Ramelmeier as chief technology officer

Clinical-stage company Adverum Biotechnologies (ADVM) Monday announced the appointment of R

Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

Dr. Ramelmeier has more than 30 years of experience in drug development and clinical and commercial chemistry, manufacturing and controls (CMC), including...

Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

Adverum stock upgraded at Chardan ahead of key readouts

Adverum Biotechnologies (ADVM) traded ~7% higher pre-market Friday after Chardan Capital upgraded it citing upcoming data for its lead asset ADVM-022. Read more here.

Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

- LUNA 14-week data on aflibercept protein levels anticipated in the third quarter of 2023 and preliminary efficacy and safety data anticipated in the...

Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid

Adverum has granted Ray Therapeutics a non-exclusive, royalty-bearing license for the use of Adverum’s proprietary intravitreal AAV.7m8 vector capsid...

Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference

REDWOOD CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

Adverum Biotechnologies Announces New Executive Leadership Roles

- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor - - Star Seyedkazemi, Pharm.D., chief development officer, expands...